Personal information

Keywords

Vaccine, immunology, virology, microbiology, antibody, monoclonal antibody

Countries

United States

Activities

Collapse all

Employment (4)

Conigen Bioscience, Inc.: WORCESTER, MA, US

2023-05-08 to present | Chief Scientific Officer
Employment
Source: Self-asserted source
Shixia Wang

Vaxxinity, Inc: Dallas, US

2021-09-01 to 2023-05-07
Employment
Source: Self-asserted source
Shixia Wang

Worcester HIV Vaccine, Inc.: Worcester, MA, US

2018-07-01 to 2021-08-31
Employment
Source: Self-asserted source
Shixia Wang

University of Massachusetts Medical School: Worcester, MA, US

1996-05-01 to 2021-08-31
Employment
Source: Self-asserted source
Shixia Wang

Education and qualifications (1)

Chinese Academy of Preventive Medicine: Beijing, CN

1992 to 1995 | PhD
Education
Source: Self-asserted source
Shixia Wang

Works (5)

Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains

Nature Communications
2024-05-21 | Journal article
DOI: 10.1038/s41467-024-48514-8
Contributors: Shixia Wang; Kun-Wei Chan; Danlan Wei; Xiuwen Ma; Shuying Liu; Guangnan Hu; Saeyoung Park; Ruimin Pan; Ying Gu; Alexandra F. Nazzari et al.
Source: check_circle
Crossref

RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques

Vaccines
2023-12-29 | Journal article
DOI: 10.3390/vaccines12010040
Contributors: Shixia Wang; Farshad Guirakhoo; Sivakumar Periasamy; Valorie Ryan; Jonathan Wiggins; Chandru Subramani; Brett Thibodeaux; Jaya Sahni; Michael Hellerstein; Natalia A. Kuzmina et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains

2023-10-20 | Preprint
DOI: 10.21203/rs.3.rs-3360161/v1
Contributors: Shan Lu; Shixia Wang; Kun-Wei Chan; Danlan Wei; Xiuwen Ma; Shuying Liu; Guangna Hu; Saeyoung Park; Ruimin Pan; Ying Gu et al.
Source: check_circle
Crossref

High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster

The Journal of Infectious Diseases
2022-10-17 | Journal article
DOI: 10.1093/infdis/jiac241
Contributors: Farshad Guirakhoo; Shixia Wang; Chang Yi Wang; Hui Kai Kuo; Wen Jiun Peng; Hope Liu; Lixia Wang; Marina Johnson; Adam Hunt; Mei Mei Hu et al.
Source: check_circle
Crossref

High neutralizing antibody levels against SARS-CoV-2 Omicron BA.1 and BA.2 after UB-612 vaccine booster

2022-03-21 | Preprint
DOI: 10.1101/2022.03.18.484436
Contributors: Farshad Guirakhoo; Shixia Wang; Chang Yi Wang; Hui-Kai Kuo; Wen-Jiun Peng; Hope Liu; Lixia Wang; Marina Johnson; Adam Hunt; Mei Mei Hu et al.
Source: check_circle
Crossref

Peer review (1 review for 1 publication/grant)

Review activity for npj vaccines. (1)
How many people are using ORCID?